204 related articles for article (PubMed ID: 22213451)
1. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Gunzburg MJ; Ambaye ND; Del Borgo MP; Pero SC; Krag DN; Wilce MC; Wilce JA
J Mol Recognit; 2012 Jan; 25(1):57-67. PubMed ID: 22213451
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of binding by cyclic nonphosphorylated peptide antagonists of Grb7 implicated in breast cancer progression.
Ambaye ND; Pero SC; Gunzburg MJ; Yap M; Clayton DJ; Del Borgo MP; Perlmutter P; Aguilar MI; Shukla GS; Peletskaya E; Cookson MM; Krag DN; Wilce MC; Wilce JA
J Mol Biol; 2011 Sep; 412(3):397-411. PubMed ID: 21802427
[TBL] [Abstract][Full Text] [Related]
3. Uptake of a cell permeable G7-18NATE contruct into cells and binding with the Grb-7-SH2 domain.
Ambaye ND; Lim RC; Clayton DJ; Gunzburg MJ; Price JT; Pero SC; Krag DN; Wilce MC; Aguilar MI; Perlmutter P; Wilce JA
Biopolymers; 2011; 96(2):181-8. PubMed ID: 20564009
[TBL] [Abstract][Full Text] [Related]
4. Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation.
Porter CJ; Matthews JM; Mackay JP; Pursglove SE; Schmidberger JW; Leedman PJ; Pero SC; Krag DN; Wilce MC; Wilce JA
BMC Struct Biol; 2007 Sep; 7():58. PubMed ID: 17894853
[TBL] [Abstract][Full Text] [Related]
5. NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein.
Porter CJ; Wilce JA
Biopolymers; 2007; 88(2):174-81. PubMed ID: 17206629
[TBL] [Abstract][Full Text] [Related]
6. Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target.
Watson GM; Gunzburg MJ; Ambaye ND; Lucas WA; Traore DA; Kulkarni K; Cergol KM; Payne RJ; Panjikar S; Pero SC; Perlmutter P; Wilce MC; Wilce JA
J Med Chem; 2015 Oct; 58(19):7707-18. PubMed ID: 26359549
[TBL] [Abstract][Full Text] [Related]
7. Preparation and crystallization of the Grb7 SH2 domain in complex with the G7-18NATE nonphosphorylated cyclic inhibitor peptide.
Yap MY; Wilce MC; Clayton DJ; Perlmutter P; Aguilar MI; Wilce JA
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Dec; 66(Pt 12):1640-3. PubMed ID: 21139214
[TBL] [Abstract][Full Text] [Related]
8. Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target.
Watson GM; Lucas WAH; Gunzburg MJ; Wilce JA
Front Mol Biosci; 2017; 4():64. PubMed ID: 29018805
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity.
Sang J; Kulkarni K; Watson GM; Ma X; Craik DJ; Henriques ST; Poth AG; Benfield AH; Wilce JA
Molecules; 2019 Oct; 24(20):. PubMed ID: 31627265
[TBL] [Abstract][Full Text] [Related]
10. Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7.
Gunzburg MJ; Kulkarni K; Watson GM; Ambaye ND; Del Borgo MP; Brandt R; Pero SC; Perlmutter P; Wilce MC; Wilce JA
Sci Rep; 2016 Jun; 6():27060. PubMed ID: 27257138
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the human Grb14-SH2 domain and comparison with the structures of the human Grb7-SH2/erbB2 peptide complex and human Grb10-SH2 domain.
Scharf PJ; Witney J; Daly R; Lyons BA
Protein Sci; 2004 Sep; 13(9):2541-6. PubMed ID: 15322292
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
Pero SC; Shukla GS; Cookson MM; Flemer S; Krag DN
Br J Cancer; 2007 May; 96(10):1520-5. PubMed ID: 17426702
[TBL] [Abstract][Full Text] [Related]
13. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Development, and Cellular Delivery of Potent and Selective Bicyclic Peptide Inhibitors of Grb7 Cancer Target.
Watson GM; Kulkarni K; Sang J; Ma X; Gunzburg MJ; Perlmutter P; Wilce MCJ; Wilce JA
J Med Chem; 2017 Nov; 60(22):9349-9359. PubMed ID: 29083893
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7.
Pero SC; Oligino L; Daly RJ; Soden AL; Liu C; Roller PP; Li P; Krag DN
J Biol Chem; 2002 Apr; 277(14):11918-26. PubMed ID: 11809769
[TBL] [Abstract][Full Text] [Related]
16. Development of binding assays for the SH2 domain of Grb7 and Grb2 using fluorescence polarization.
Luzy JP; Chen H; Gril B; Liu WQ; Vidal M; Perdereau D; Burnol AF; Garbay C
J Biomol Screen; 2008 Feb; 13(2):112-9. PubMed ID: 18216394
[TBL] [Abstract][Full Text] [Related]
17. Preparation of crystals for characterizing the Grb7 SH2 domain before and after complex formation with a bicyclic peptide antagonist.
Ambaye ND; Gunzburg MJ; Traore DA; Del Borgo MP; Perlmutter P; Wilce MC; Wilce JA
Acta Crystallogr F Struct Biol Commun; 2014 Feb; 70(Pt 2):182-6. PubMed ID: 24637751
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for dimerization of the Grb10 Src homology 2 domain. Implications for ligand specificity.
Stein EG; Ghirlando R; Hubbard SR
J Biol Chem; 2003 Apr; 278(15):13257-64. PubMed ID: 12551896
[TBL] [Abstract][Full Text] [Related]
19. Design and testing of bicyclic inhibitors of Grb7--are two cycles better than one?
Gunzburg MJ; Ambaye ND; Del Borgo MP; Perlmutter P; Wilce JA
Biopolymers; 2013 Sep; 100(5):543-9. PubMed ID: 23505041
[TBL] [Abstract][Full Text] [Related]
20. Progress towards the development of SH2 domain inhibitors.
Kraskouskaya D; Duodu E; Arpin CC; Gunning PT
Chem Soc Rev; 2013 Apr; 42(8):3337-70. PubMed ID: 23396540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
